support@mellalta.com   +1 (304) 470-2225

Actinium’s Multi-billion Dollar Market for Targeted Conditioning with their revolutionary Antibody Warhead Enabling (AWE) platform!

Actinium Pharmaceuticals’ Antibody Warhead Enabling (AWE) Future Opportunities

Actinium Pharmaceuticals is a clinical stage biopharmaceutical company, with an impressive Antibody Warhead Enabling (AWE) technology. The technology enables the development of breakthrough Antibody Radiation-Conjugates (ARCs), that combine the targeting ability of antibodies with the […]

Read More

Development & Marketing Strategy behind, Daiichi Sankyo’s DS-1062, $6 billion deal with AstraZeneca

Daiichi Sankyo unveiled about the collaboration between them and AstraZeneca for antibody drug conjugate, DS-1062. This news has created absolute havoc in the Pharma market. As per the agreement, AstraZeneca will pay Daiichi Sankyo up […]

Read More

Multiple System Atrophy’s Competitive Landscape 2020

Multiple system atrophy (MSA) is a rare, degenerative neurological disorder affecting your body’s involuntary (autonomic) functions, including blood pressure, breathing, bladder function and motor control. MSA shares many Parkinson’s disease-like symptoms, such as slow movement, rigid […]

Read More

Revamp Medical’s Doraya catheter breakthrough designation by FDA provides a whole new vision for treating Acute Heart Failure

Revamp Medical’s Doraya catheter [Breakthrough Device Designation]

Revamp Medical’s Doraya catheter is designed to improve the efficacy of diuretic therapy in patients with acute heart failure (AHF). Heart failure is a chronic, progressive disease complex clinical syndrome that results from any functional […]

Read More

How selinexor (Xpovio) is positioned in competitive R/R DLBCL market?

SELINEXOR-XPOVIO-COMPETITIVE-POSITIONING-IN-DLBCL

Karyopharm’s Selinexor (Xpovio)  an oral selective inhibitor of nuclear export (SINE) compound inhibiting the nuclear export protein exportin 1 (XPO1) was granted accelerated approval for the treatment of adults with relapsed or refractory diffuse large […]

Read More

Bristols’ DLBCL CAR-T Therapy -Lisocabtagene Maraleucel (JCAR017) Future Strategy & Latest Events

Liso-cel Strategy

Lisocabtagene maraleucel, also known as liso-cel and JCAR017 is a 4-1BB-based second generation CAR-T therapy, that contains a distinct IgG4-based hinge. The therapy is a key pipeline asset which Bristol-Myers picked up through its takeover […]

Read More

The Next level Digital Consolidation — Digital Operation Room by Brainlab and Medical-training video games by Level Ex, designed for SURGEONS

The acquisition of Level Ex by Brainlab marks this the first acquisition of a video game company by a major international healthcare company reflecting the growing popularity of gamified products. Key Takeaways! Future Strategy The […]

Read More

Gene Research collaboration of Cabaletta Bio’s CABA Platform (CAART cell therapy) & Artisan Bio’s STARS Platform (Genome engineering)

Cabeletta-Bio-Artisian-Bio-CARRT-Cell-Therapy

Artisan bio entered into a gene editing research agreement with Cabaletta, which allows it to integrate Artisan’s advanced gene editing and engineering technology into Cabeletta’s next-generation CAAR T products as the company continues to expand […]

Read More

Pfizer and Sidekick’s digital therapeutics platform to connect PAP, KOLs, Stakeholders and Patient panels

Pfizer and-SideKick Digital Therapeutics Platform

Nordic digital therapeutics company SidekickHealth entered a deal with Pfizer to launch a disease management platform in Europe. Pfizer continues to be at the forefront of the transformation of medicine and with SidekickHealth, aims to […]

Read More

Daiichi Sankyo’s Well-Written Market Positioning Strategy for DS-1062 (Antibody Drug Conjugate) in TNBC and NSCLC Landscape

Daiichi Sankyo’s DS-1062 is a TROP2-directed antibody drug conjugate (ADC), designed using Daiichi Sankyo’s proprietary DXd ADC technology with the highest development stage of Phase I. We, Mellalta Meets, unveil the Daiichi’s strategies with the […]

Read More

Get In Touch

Let's keep the conversation going